Shots:

• BioVectra to provide its integrated CDMO services for the manufacturing of API of bentracimab for use in PhaseBio’s ongoing global studies and global commercial use upon regulatory approval
• PhaseBio plans to integrate API manufactured at a commercial scale at BioVectra into the ongoing P-IIb and P-III REVERSE-IT study to support the global regulatory filings
• The agreement will enable PhaseBio to supply bentracimab at launch in the US. Bentracimab is a monoclonal antibody fragment that demonstrated immediate and sustained reversal of the antiplatelet activity of Brilinta (ticagrelor)

 ­ Ref: Businesswire | Image: Businesswire